M&A
confidence high
sentiment positive
materiality 0.80
Eton licenses late-stage ASN-001 (timolol gel) for infantile hemangiomas; $3M upfront
Eton Pharmaceuticals, Inc.
- Upfront license fee $3M to Auson; milestones up to $33.5M based on sales thresholds; tiered royalties 10-15%.
- Phase II/III trial: 56% (BID) and 42% (TID) elimination/near-elimination at week 24 vs 15% placebo.
- NDA submission planned for 2H 2027; potential approval and launch in 2028.
- Estimated 20,000-30,000 patients annually; complementary to HEMANGEOL, leveraging existing commercial infrastructure.
- Patent protection through 2044; additional patent application pending.